Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vivoryon Therapeutics has announced promising results from its Phase 2b study of varoglutamstat, showing significant improvement in kidney function, particularly among diabetic patients. The drug demonstrated an excellent safety profile and may offer a new treatment approach for diabetic kidney disease and other kidney disorders. The company plans further studies to confirm these effects.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.